Genomics promising in post-nephrectomy risk stratification
Genomics may ultimately play an important role in determining recurrence risk in patients who undergo surgery for localized kidney cancer, according to Brian Rini, MD, of Cleveland Clinic.
Genomics may ultimately play an important role in determining recurrence risk in patients who undergo surgery for localized kidney cancer, according to Brian Rini, MD, of Cleveland Clinic.
In a presentation at the Genitourinary Cancers Symposium in San Francisco, Dr. Rini discussed current models to estimate recurrence risk and the development and validation of a 16-gene RT-PCR renal cancer assay. A large candidate-based gene expression analysis was conducted on approximately 1,000 tumor samples.
“We boiled it down to 16 genes that were associated with recurrence,” he explains in this Urology Times video. But the gene signature is not ready for prime time.
“Slowly we’re making some progress into integrating genomics, and I’m hopeful in the next few years we can do a better job in kidney cancer” that would equate to what is being done with genomics in breast and colon cancer, Dr. Rini said.
Dr. Rini receives honoraria from Bristol-Myers Squibb; is a consultant/adviser to Novartis, Pfizer, Merck, and Roche/Genentech; and receives travel, accommodations, or expenses from Pfizer.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
